AMCAP™: One-Pot mRNA Capping Technology
A smarter, faster way to combine transcription and capping in a single reaction.
Anemocyte is a proud member of:
Choose how you bring AMCAP™ technology into your workflow.
Evolving the enzymatic mRNA manufacturing
AMCAP™ is Anemocyte’s proprietary, patent-pending one-pot technology for mRNA synthesis a smarter, faster way to combine transcription and capping in a single reaction.
Unlike standard two-step methods or matching the Co-trascriptional method, AMCAP™ delivers efficiency, flexibility, and high-quality results with fewer steps and lower costs.
The Power of One Reaction
By merging transcription and capping into one seamless process, AMCAP™ enables rapid synthesis of 5’ CAP-1 mRNA with excellent yield, purity, and expression performance. Its unique design reduces process time and downstream operations, while maintaining superior mRNA integrity.
AMCAP™ technology delivers a significant higher level of Cap1 structure on the 5′ end of the mRNA than the standard two step enzymatic method. Capping efficiency and protein expression are comparable to method based on co-transcriptional capping.
Flexible, Scalable, Proven
AMCAP™ is designed for flexibility – compatible with a wide range of commercially available reagents and adaptable to specific research goals: yield maximization, capping optimization, or enhanced protein expression.
AMCAP™ represents the next evolution in mRNA manufacturing.
It has been developed by Anemocyte, a Biotech Manufacturing Organization (BMO) with over 25 years of experience in innovative medicine in the field of Cell and Gene Therapy and nucleic acid.
Choose how you bring AMCAP™ technology into your workflow.
Join the enzymatic capping evolution of mRNA synthesis: faster, simpler, smarter.
Anemocyte is a proud member of: